Accelerating discovery science to clinical translation: CiC3 - The Oxford MRC CiC Pipeline

Lead Research Organisation: University of Oxford

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Dean BJ (2016) The Effects of Glucocorticoid on Tendon and Tendon Derived Cells. in Advances in experimental medicine and biology

publication icon
Hancock G (2018) Therapeutic HPV vaccines in Best Practice & Research Clinical Obstetrics & Gynaecology

publication icon
Stace ET (2016) Translating Regenerative Biomaterials Into Clinical Practice. in Journal of cellular physiology

 
Description 'Frontiers of Science' A comparative study on diseases caused by the endemic and emerging viral agents Dengue, Chikungunya and Zika.
Amount $4,000,000 (MXN)
Funding ID Project No. 1192 
Organisation National Council on Science and Technology (CONACYT) 
Sector Public
Country Mexico
Start 09/2016 
End 08/2019
 
Description Action Duchenne translational research
Amount £48,000 (GBP)
Organisation Action Duchenne 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2015 
End 02/2018
 
Description Anaptysbio Research Grant
Amount £700,000 (GBP)
Organisation AnaptysBio 
Sector Private
Country United States
Start 02/2017 
End 01/2019
 
Description British Medical Association
Amount £35,000 (GBP)
Organisation British Medical Association (BMA) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2012 
End 09/2014
 
Description British Skin Foundation Grant
Amount £62,000 (GBP)
Organisation British Skin Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2014 
End 12/2015
 
Description British Skin Foundation Large Research Awards
Amount £70,000 (GBP)
Organisation British Skin Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2008 
End 09/2011
 
Description Cancer Immunology Project award
Amount £287,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 03/2019
 
Description Celgene Fellowship
Amount £500,000 (GBP)
Organisation Bristol-Myers Squibb 
Department Celgene
Sector Private
Country United States
Start 01/2016 
End 01/2020
 
Description Clinical Biomanufacture of Nanofibre scaffolds for soft tissue repair
Amount £75,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2015 
End 05/2016
 
Description Comprehensive Research Network
Amount £1,700,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Clinical Research Network (CRN)
Sector Academic/University
Country United Kingdom
Start 04/2007 
End 03/2017
 
Description Confidence in Concept
Amount £4,800 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 02/2018
 
Description Confidence in Concept (CiC) by MRC
Amount £100,023 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2015 
End 06/2016
 
Description Duchenne UK translational research
Amount £50,000 (GBP)
Organisation Duchenne UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2015 
End 02/2018
 
Description EXPLORATORY/DEVELOPMENT GRANT
Amount $137,000 (USD)
Funding ID 1R21AI125886-01 
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 09/2016 
End 08/2018
 
Description EvOx
Amount £10,000,000 (GBP)
Organisation EvOx Therapeutics 
Sector Private
Country United Kingdom
Start 05/2016 
End 02/2018
 
Description Evox
Amount £650,000 (GBP)
Organisation EvOx Therapeutics 
Sector Private
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description Janssen collaborative research grant
Amount $1,600,000 (USD)
Organisation Johnson & Johnson 
Department Janssen Pharmaceuticals
Sector Private
Country United States
Start 10/2013 
End 09/2015
 
Description John Fell Fund
Amount £14,970 (GBP)
Funding ID 0006270 
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 01/2020
 
Description Johnson and Johnson collaborative research
Amount £100,000 (GBP)
Organisation Johnson & Johnson 
Sector Private
Country United States
Start 01/2015 
End 12/2015
 
Description MRC Experimental Medicine 2
Amount £380,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2009 
End 09/2012
 
Description MRC/UCB Antibody Discovery Initiative
Amount £250,000 (GBP)
Funding ID MC_EX_MR/R022550/1 
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 02/2019 
End 12/2019
 
Description NIHR Senioe Investigator
Amount £60,000 (GBP)
Organisation University of Leicester 
Department NIHR Biomedical Research Centre
Sector Hospitals
Country United Kingdom
Start 04/2018 
End 03/2022
 
Description New vaccines for global epidemics: development and manufacture
Amount £488,611 (GBP)
Funding ID TSB File Ref.: 972214. Application No. 71744-493192 
Organisation SBRI Healthcare 
Sector Private
Country United Kingdom
Start 10/2016 
End 09/2017
 
Description Oxford Biomedical Research Centre
Amount £1,000,000 (GBP)
Organisation Oxford University Hospitals NHS Foundation Trust 
Department NIHR Oxford Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 04/2007 
End 03/2017
 
Description PepGen: Peptide platform
Amount £68,000 (GBP)
Organisation Charley's Fund 
Sector Charity/Non Profit
Country United States
Start 06/2017 
End 01/2019
 
Description UCB Research grant
Amount £354,000 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 09/2016 
End 08/2018
 
Description Use of High-Definition immune profiling to understand mechanisms underpinning control of high-risk Human Papillomavirus (hrHPV) in exposed women
Amount £15,000 (GBP)
Funding ID CRUKDF 0119-JK 
Organisation University of Oxford 
Sector Academic/University
Country United Kingdom
Start 03/2019 
End 03/2020
 
Description Wellcome Trust Collaboratiev Award
Amount £3,000,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 04/2023
 
Title PBMC samples, serum and vaginal specimens from healthy women with exposure to high risk HPV 
Description Prospective longitudinal collection of PBMC samples, serum and self-taken vaginal swabs for DNA extraction and testing for high risk HPV obtained from women aged 16-55 with current or prior exposure - Ethics ref: 16/SW/0331. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? No  
Impact PBMC samples are being tested for T cells specific for HPV sequences in our vaccine and circulating in the population. Vaginal samples are tested for high risk HPV DNA. Serum will be tested for HPV-specific neutralising antibodies at PHE reference laboratory. 
 
Description Development of a multi-genotype therapeutic vaccine for pre-invasive high risk human papillomavirus disease (hrHPV) 
Organisation Vaccitech Ltd
Country United Kingdom 
Sector Private 
PI Contribution Developed therapeutic HPV vaccines using chimpanzee adenovirus and MVA vectors to deliver a novel immunogen.
Collaborator Contribution Provided know-how and finances to undertake pre-GMP work prior to manufacture of GMP lots for clinical trial.
Impact N/A
Start Year 2017
 
Description License option taken by Roche ventana 
Organisation Ventana Systems Inc
Country United States 
Sector Private 
PI Contribution License option taken by Roche ventana to develop our technology to a diagnostic test.
Collaborator Contribution Roche Ventana will validate and obtain the necessary approvals to proceed towards a diagnostic test
Impact License option
Start Year 2017
 
Title Adenosine receptor modulators 
Description We have developed a range of modulators to manage diseases associated with circadian rhythm disturbances. This could be of great utility in managing a multitude of orphan disorders associated with circadian rhythm disorders such as non-24 sleep wake disorder, advanced sleep phase syndrome and also other potential mainstream mood related disorders. Towards this we have identified a range of molecules and demonstrated their validity in a range of preclinical in vitro and in vivo models of the disease. 
IP Reference GB1606622.7 
Protection Patent application published
Year Protection Granted 2016
Licensed Yes
Impact This has resulted in establishing a new spin out "circadian therapeutics" and we are now seeking protection internationally.
 
Title DENGUE VACCINES 
Description The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions,nucleic acids, viral vectors, virus- like particles, use,prime boost vaccination kits, agents and methods. 
IP Reference WO2016181147 
Protection Patent application published
Year Protection Granted 2016
Licensed Commercial In Confidence
Impact Dengue vaccine for commercialisation
 
Title Development of a test for T celllymphoma/leukaemia 
Description We have developed a potential test for T cell lymphoma which may have future theraeutic relevance. 
IP Reference WO2016051205 
Protection Patent application published
Year Protection Granted 2014
Licensed Commercial In Confidence
Impact Academic work continues in order to validate the technology. Commercial interactions currently under negotiation.
 
Title HPV VACCINE 
Description The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis. 
IP Reference WO2019034887 
Protection Patent application published
Year Protection Granted 2019
Licensed Yes
Impact None
 
Company Name Evox Therapeutics 
Description Exosome therapeutic technology company 
Year Established 2016 
Impact Development of therapeutic exosome technology. Investment from Oxford Sciences Innovation
Website http://www.evoxtherapeutics.com
 
Company Name PepGen 
Description PepGen, a new Oxford University Innovation spin out company. 
Year Established 2018 
Impact Co-development with a pharmaceutical company in order to develop a novel multi-exon skipping approach with high efficiency for all DMD patients.
 
Description "Cut & Paste" - genome editing (Royal Institution Family Fun day) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact "Cut & Paste" - genome editing activities at the Royal Institution Family Fun day on 22nd February 2019. It comprised three activities explaining genome editing and its utilisation as a research tool
Year(s) Of Engagement Activity 2019
 
Description "Understanding allergy - Itching, sneezing, wheezing" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Two 30 minute talks to 9/10 year students explaining the immune system and allergy. The talks were part of Wadham College Aspiration day 4th March 2019 - Academic taster session.
Year(s) Of Engagement Activity 2019
 
Description Dementia Friends - Public Engagement Event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact This was a regional event organised by Dementia Friendly Chipping Norton, including a Dementia Friends Information Session, a couple of short research talks, and a panel Q&A. I contributed a talk and was a panel member.
Year(s) Of Engagement Activity 2017
 
Description Oxford biotech deals highlight stature of UK university spinouts 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact http://www.evoxtherapeutics.com/news/2016/5/11/oxford-biotech-deals-highlight-stature-of-uk-university-spinouts
Year(s) Of Engagement Activity 2016
URL http://www.evoxtherapeutics.com/news/2016/5/11/oxford-biotech-deals-highlight-stature-of-uk-universi...
 
Description RB visit to University of Oxford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Gave short presentation on my HPV vaccine programme with a view to exploring interest in future partnership / funding.
Year(s) Of Engagement Activity 2017
 
Description Science club at Freeland Primary School 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Visit to Freeland Primary School on 14th January 2020 to carry out a 1h session comprising three activities with primary school students to explain DNA and genome editing.
Year(s) Of Engagement Activity 2020
 
Description Seminar to OUHT Microbiology department 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Gave an overview of research leading to my CRUK funded project, how this project would address significant knowledge gaps and what the Microbiology department would learn from our study.
Also suggested ideas for collaborations with members of the department.
Year(s) Of Engagement Activity 2017
 
Description T cell differentation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact 1h session during Biology Summer School which took place at Wadham College on 21st August 2019. The activity looked at how naïve T cells differentiate into T cell subsets in vitro.
Year(s) Of Engagement Activity 2019
 
Description The Immune Cell Highway 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact The Immune Cell Highway was a session organised for Superdads Playgroup at Northway Church, Oxford on 8th February 2020. The activities were aimed at explaining how immune cells move around the body via two pathways - the blood & the lymphatics - and how this travelling is essential for clearing infections in the skin.
Year(s) Of Engagement Activity 2020
 
Description The Immune Cell Highway (Swindon Science Festival) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Immune Cell Highway activity links the work being done in the Dong, Ogg and Jackson labs in the WIMM. They have created a stand explaining how immune cells move around the body via two pathways: the blood & the lymphatics. This activity was part of Swindon Science Festival on 21st and 22nd February 2020.
Year(s) Of Engagement Activity 2020
 
Description UKSF - Liverpool Research Training Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The Stroke Research Training Day is aimed at those who want to get involved in research for the first time as well as those who have already started in a research career.

Around 85 delegates attended.
The training day combined presentations and expert coaching by the Stroke Association Lecturers. This interactive day set out a compelling case for stroke research, described the main studies going on right now, and looked at future horizons. We explored funding opportunities, the role of the Research Design Service and the critical role that people affected by stroke play in the research process. 
Hands on coaching sessions included: how to create a poster and give a talk; how to balance clinical and research interests; how to respond to peer review comments; choosing the right research methods.  
Year(s) Of Engagement Activity 2015,2016,2017
URL https://www.stroke.org.uk/uksf-conference
 
Description Understanding allergy - Itching, sneezing, wheezing 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Two 30 minute sessions doing an "allergy testing" experiment with 9/10 year students. These sessions were part of Wadham College Aspiration Day - Academic taster session on 10th May 2019.
Year(s) Of Engagement Activity 2019